At JDRF’s Artificial Pancreas Program, we are working to provide technology that is small, user-friendly and accurate, so that people with type 1 diabetes (T1D) can get through the day without needing to check blood-sugar levels or dose insulin as often.
In people with T1D, the body often defies even the most vigilant efforts to keep blood-sugar levels normal. Artificial pancreas systems, however, take over much of the blood-sugar management. They monitor blood-glucose levels with a continuous glucose monitor (CGM) and use an algorithm to automatically provide the right amount of insulin at the right time—much like a normal pancreas would do naturally.
that go unnoticed by everyone but the wearer
so an insulin pump, a CGM and algorithm can “talk” to each other, regardless of the manufacturer
to control blood sugar automatically, even while eating or exercising
“Before I had an artificial pancreas system, I would constantly check my glucose levels to make sure I wasn’t getting too low or too high. Now, my artificial pancreas does it for me, and provides insulin as a result of its readings. Because of this, I think about T1D a fraction of the time, leading me to focus my efforts on more important things.” Sara K.30 years old, diagnosed at age 8
“Before I had an artificial pancreas system, I would constantly check my glucose levels to make sure I wasn’t getting too low or too high. Now, my artificial pancreas does it for me, and provides insulin as a result of its readings. Because of this, I think about T1D a fraction of the time, leading me to focus my efforts on more important things.”
Sara K.30 years old, diagnosed at age 8
Our research into artificial pancreas devices and technologies is just one potential pathway to finding a cure for T1D. Explore JDRF’s ambitious research portfolio.
A growing number of people have used do-it-yourself (DIY) approaches to “hack” their continuous glucose monitors (CGMs) and insulin pumps to allow them to work together as an automated insulin delivery system.
JDRF’s Coverage2Control campaign convinces America’s second-largest health insurance company, to cover the artificial pancreas systems.
JDRF announces funding for SFC Fluidics to develop an insulin patch pump with open protocol communication capabilities.
JDRF and Ypsomed, a Switzerland-based developer and manufacturer of injection and infusion systems, partnere as part of JDRF’s Open Protocol Automated Insulin Delivery (AID) Systems Initiative.
To date, more than $110 million has been invested by JDRF. Future research will continue to automate blood-sugar management, dramatically reduce T1D-related risks and reduce the burden on people living with the disease.
Blog
Community Story
Article
